N Nanobiotix
N
Ouvert
29.9 -1.97
Résumé
Variation du prix de l'action
24h
Min
29.7
Max
30.5
Revenu | -13M -19M |
|---|---|
Ventes | -24M 3M |
Marge bénéficiaire | -618.236 |
Employés | 100 |
EBITDA | -14M -13M |
Recommandations | Achat Fort |
|---|---|
Prévisions sur 12 Mois | +81.4% upside |
Prochains Résultats | 23 juin 2026 |
|---|
Capitalisation Boursière | 277M 1.6B |
|---|---|
Ouverture précédente | 31.87 |
Clôture précédente | 29.9 |
Nanobiotix Graphique
Les performances passées ne sont pas un indicateur fiable des résultats futurs.
À Propos Nanobiotix
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.
